{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:03:50Z","timestamp":1781762630061,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.lungcan.2020.02.011","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T20:46:48Z","timestamp":1583786808000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer"],"prefix":"10.1016","volume":"144","author":[{"given":"Solange","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5789","authenticated-orcid":false,"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Abbattista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson","family":"Peltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ross Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2020.02.011_bib0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/17512433.2019.1570846","article-title":"Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.lungcan.2020.02.011_bib0010","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.lungcan.2020.02.011_bib0015","doi-asserted-by":"crossref","first-page":"53336","DOI":"10.18632\/oncotarget.18408","article-title":"Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS\/EGFR\/HER2\/BRAF\/PIK3CA\/ALK alterations","volume":"8","author":"Dugay","year":"2017","journal-title":"Oncotarget"},{"issue":"46","key":"10.1016\/j.lungcan.2020.02.011_bib0020","doi-asserted-by":"crossref","first-page":"75145","DOI":"10.18632\/oncotarget.12612","article-title":"Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0025","first-page":"360","volume":"37","author":"Facchinetti","year":"2018"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0030","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.2147\/OTT.S165511","article-title":"Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date","volume":"11","author":"Akamine","year":"2018","journal-title":"Onco. Ther."},{"key":"10.1016\/j.lungcan.2020.02.011_bib0035","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejmech.2017.04.032","article-title":"First macrocyclic 3(rd)-generation ALK inhibitor for treatment of ALK\/ROS1 cancer: clinical and designing strategy update of lorlatinib","volume":"134","author":"Basit","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.lungcan.2020.02.011_bib0040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/CAD.0000000000000525","article-title":"Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient","volume":"28","author":"Hochmair","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"12","key":"10.1016\/j.lungcan.2020.02.011_bib0045","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2020.02.011_bib0050","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.02.011_bib0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Lorlatinib: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0060","series-title":"Lobrena (lorlatinib) Package Insert","year":"2018"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0065","series-title":"Summary of Product Characteristics","year":"2019"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0070","series-title":"Report on the Deliberation Results","year":"2018"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0075","series-title":"LORBRENA Lorlatinib Tablets","year":"2019"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejpb.2019.01.016","article-title":"Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK\/ROS1 inhibitor lorlatinib","volume":"136","author":"Li","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.lungcan.2020.02.011_bib0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.5306\/wjco.v4.i4.82","article-title":"Are the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important?","volume":"4","author":"Hirsh","year":"2013","journal-title":"World J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.02.011_bib0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/lmt-2016-0010","article-title":"Measurement of quality of life in second-line patients with advanced NSCLC without targetable mutations: a review","volume":"5","author":"Heigener","year":"2016","journal-title":"Lung Cancer Manag."},{"issue":"5","key":"10.1016\/j.lungcan.2020.02.011_bib0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.lungcan.2020.02.011_bib0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12955-018-1012-x","article-title":"Assessing whether EORTC QLQ-30 and FACT-G measure the same constructs of quality of life in patients with total laryngectomy","volume":"16","author":"Iravani","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"issue":"1","key":"10.1016\/j.lungcan.2020.02.011_bib0105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jclinepi.2013.02.019","article-title":"The quality of life questionnaire core 30 (QLQ-C30) and Functional Assessment of Cancer-General (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size","volume":"67","author":"King","year":"2014","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.02.011_bib0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1524-4733.2008.00405.x","article-title":"Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data","volume":"12","author":"McKenzie","year":"2009","journal-title":"Value Health"},{"issue":"24","key":"10.1016\/j.lungcan.2020.02.011_bib0115","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1002\/cncr.29682","article-title":"Use of the lung cancer-specific quality of life questionnaire EORTC QLQ-LC13 in clinical trials: a systematic review of the literature 20 years after its development","volume":"121","author":"Koller","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2020.02.011_bib0120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0125","series-title":"Published by: European Organisation for Research and Treatment of Cancer","article-title":"The EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"issue":"1","key":"10.1016\/j.lungcan.2020.02.011_bib0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 8","key":"10.1016\/j.lungcan.2020.02.011_bib0135","doi-asserted-by":"crossref","first-page":"viii504","DOI":"10.1093\/annonc\/mdy292.022","article-title":"Impact of Lorlatinib on Patient-Reported Outcomes in Patients With Advanced ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer","author":"Peters","year":"2018","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2020.02.011_bib0140","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0145","series-title":"Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims: Guidance for Industry","year":"2009"},{"key":"10.1016\/j.lungcan.2020.02.011_bib0150","series-title":"FDA Standard Core Clinical Outcome Assessments and Endpoints","year":"2018"},{"issue":"11","key":"10.1016\/j.lungcan.2020.02.011_bib0155","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0000000000000318","article-title":"Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer","volume":"9","author":"Blackhall","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.02.011_bib0160","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1556-0864(18)30412-X","article-title":"Patient-reported Outcomes (PROs) in ALEX: A Phase III Study of Alectinib (ALEC) Vs Crizotinib (CRIZ) in Non-small-cell Lung Cancer (NSCLC)","volume":"13","author":"Perol","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"suppl_9","key":"10.1016\/j.lungcan.2020.02.011_bib0165","doi-asserted-by":"crossref","first-page":"ix139","DOI":"10.1093\/annonc\/mdw594.008","article-title":"444PD Patient-reported outcomes (PROs) in ASCEND-5: a randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ)","volume":"27","author":"Mok","year":"2016","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:36:22Z","timestamp":1759235782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220303081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":33,"alternative-id":["S0169500220303081"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.02.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}